Cardiology in Massachusetts

Paragonix Technologies designs and manufactures advanced organ preservation systems and digital logistics platforms for the transplant community. The company specializes in controlled-temperature organ transport devices that maintain donor organs at optimal, non-freezing temperatures during procurement and transport. Product lines include SherpaPak (cardiac preservation), LUNGguard (lung preservation), BAROguard (bariatric organ preservation), LIVERguard (liver preservation), PancreasPak (pancreas preservation), and KidneyVault (kidney preservation). All devices are FDA-cleared and CE-marked. Paragonix also offers the Paragonix App, a HIPAA-compliant digital platform for real-time temperature monitoring, GPS tracking, case coordination, and event logging across transplant teams. The company operates GUARDIAN clinical registries (Heart, Lung, and Liver) representing observational databases tracking post-transplant outcomes; over 35 clinical studies have been published. Services include 24/7 clinical procurement support and case logistics management. The company supports over 180 transplant centers globally and has preserved over 10,000 donor organs. Paragonix is positioned as an integrated solution provider bridging hardware, software, clinical data, and support services to improve organ viability and transplant outcomes.

Cercare Medical A/S is a Denmark-based medical imaging software company specializing in advanced perfusion and metabolic imaging solutions for neurological and oncological applications. Founded in 2001 by Professor Kim Beuschau Mouridsen and PhD Mikkel Bo Hansen, the company develops automated, on-premise perfusion imaging software compatible with any MRI and CT scanner platform. Cercare Perfusion software generates unique biomarker maps including Capillary Transit-Time Heterogeneity (CTH), Oxygen Extraction Fraction (OEF), Cerebral Metabolic Rate of Oxygen (CMRO₂), relative Cerebral Blood Volume (rCBV), relative Cerebral Blood Flow (rCBF), and Mean Transit Time (MTT). Clinical applications include acute ischemic stroke assessment, brain tumor characterization and grading, neurodegenerative disease monitoring, and oncology applications. The Cercare Medical Neurosuite (CMN) integrates AI-enabled modules for automated detection and segmentation of hypoperfusion and ischemic core regions. The company's CBCT (cone-beam CT) perfusion capability provides real-time analysis in angiography suites, enabling direct-to-angio workflows and post-intervention assessment. Cercare operates globally with authorized distribution partners including Siemens, Terabox, AIDOC, VIZ, Sectra, and Microsoft, serving hospitals in multiple countries with over 1 million annual diagnoses supported. The software is vendor-agnostic, operates on-premise with no cloud dependency, and is designed for stroke, oncology, Alzheimer's disease, dementia, and neoplasia applications.

Coghlin Companies, Inc. is a fourth-generation contract manufacturing and engineering services company (founded 1885) specializing in the design, engineering, and precision manufacturing of complex capital equipment and medical devices. Based in Westborough, Massachusetts, with ~480 employees and $159.9M annual revenue, the company serves medical life sciences, semiconductor, robotics, and industrial sectors. Core capabilities include product engineering, design for manufacturability (DFM), prototyping, printed circuit board assembly, total system integration, and global supply chain fulfillment. Notable achievements include manufacturing 10,000 ventilators during COVID-19. Coghlin operates both industrial (Columbia Tech) and medical (Cogmedix) divisions, providing end-to-end commercialization services from concept through scalable manufacturing and aftermarket support.

Werfen is a global in vitro diagnostics company operating directly in over 30 countries and through distributors in more than 100 territories. The company develops, manufactures, and commercializes diagnostic systems, reagents, software, and services across hemostasis, acute care diagnostics, transfusion, autoimmunity, transplant, immunoassay, and clinical chemistry. Werfen's hemostasis portfolio includes in vitro diagnostic systems and reagents for diagnosing and guiding treatment of thrombotic and bleeding disorders. The acute care diagnostics line provides integrated whole-blood testing solutions for cardiovascular operating rooms, catheterization laboratories, intensive care units, and emergency departments. The transfusion division offers manual and automated solutions with serology reagents, fully automated instrumentation, data management software, and molecular products for donor-recipient compatibility. The autoimmunity segment delivers reagents and lab automation for diagnosing and monitoring autoimmune diseases. Transplant products feature molecular and antibody-based HLA assays and software for pretransplant compatibility determination and post-transplant monitoring. Clinical chemistry solutions serve chemistry and pharma-toxicology laboratories. Werfen also recently completed the acquisition of Omixon, a Budapest-based company specializing in next-generation sequencing technologies for transplant diagnostics. The company maintains a technology center in Bedford, Massachusetts, expanded in December 2024. Werfen's solutions are designed to improve patient care quality, reduce laboratory costs, ensure regulatory compliance, and enhance operational efficiency across clinical laboratory and acute care hospital settings.

Enlight Medical Technologies is a global medical technology company headquartered in Boston, Massachusetts, with research and development centers and manufacturing facilities in Boston, San Francisco, Shanghai, Beijing, and Shenzhen. The company specializes in interventional medical devices for structural heart disease, vascular intervention, and neuromodulation products. The company's core therapeutic areas include: (1) valve intervention—addressing mitral regurgitation and other valvular pathologies through catheterization-based approaches; (2) aortic and peripheral intervention—treating aortic dissection and peripheral vascular disease; (3) neuromodulation—using electrode stimulation for Parkinson's disease, epilepsy, chronic pain, and urinary incontinence; and (4) brain-computer interface (BCI) technology for neurological applications and functional enhancement. The company also develops life science and diagnostic platforms, including proteomic analysis tools aligned with the Human Protein Atlas initiative. Enlight Medical maintains GMP-certified manufacturing facilities and operates across both passive and active device platforms with AI imaging capabilities. The company holds multiple medical device licenses in China and has multiple advanced clinical-stage or submitted products. Research and development teams have 15+ years of medical device engineering and production management experience. The company was founded in Boston and has expanded significantly in China, serving structural heart disease and neuromodulation markets. As of 2023, a spinoff entity (Yinghe Brain Science) completed a Series A funding round focused on next-generation neuromodulation and BCI technology development.

Amsel Medical Corporation develops minimally invasive surgical occlusion devices for vessel and tubular structure closure. The company's primary product, SCureClamp™ with Interdigitation Occlusion Technology (iDOT™), is a mechanical surgical clamping device FDA-cleared and CE-marked for closing blood vessels, arteries, veins, and ducts during surgical and interventional procedures. The device employs a unique transfixing mechanism delivered through an 18-gauge needle, providing permanent, non-chemical, non-thermal occlusion similar to hand-sewn transfixion sutures. Key design features include anchoring technology to prevent slippage, accommodation of vessels 2.0–7.0 mm in diameter, and ultrasound-guided deployment. Amsel's SCureClamp targets multiple surgical specialties including vascular surgery, general surgery (bariatric, cardiac, oncology), trauma management, and interventional radiology. In vascular applications, the device addresses limitations of current perforator treatments (lasers, RF, glue, sclerotherapy), which average 75–80% efficacy and lack permanent solutions. Clinical evidence from peer-reviewed publications in the Journal of Vascular Surgery, Surgical Endoscopy, and Journal of Surgical Research demonstrates preclinical efficacy in porcine models. The company is also developing a temporary clamping variant for military trauma applications, specifically targeting non-compressible and junctional hemorrhage in prehospital environments. Amsel Medical was awarded a prestigious U.S. Air Force AFWERX Phase 2 SBIR grant for this development. The company's devices are indicated for use by vein physicians, general surgeons, vascular surgeons, cardiovascular surgeons, interventional radiologists, and military medical personnel. Manufacturing and regulatory compliance align with FDA 510(k) and CE Mark standards.

CSA Medical, Inc. is a medical device company focused on developing spray cryotherapy solutions for interventional pulmonary therapies. The company's flagship product, RejuvenAir® System, is an investigational cryosurgical device designed to treat chronic obstructive pulmonary disease (COPD) with chronic bronchitis by applying metered doses of liquid nitrogen at −196°C to damaged airway tissue. The technology targets the underlying cause of chronic bronchitis—dysfunctional cilia and excessive mucus production—by selectively destroying diseased cells while preserving the extracellular matrix, enabling regeneration of healthy airway tissue with minimal scarring. The RejuvenAir System is delivered through a minimally invasive bronchoscopic procedure, typically performed on an outpatient or same-day basis. The company is advancing the device through the SPRAY-CB pivotal clinical trial, a multi-center interventional pulmonology study across leading academic medical centers nationwide. In January 2026, CSA Medical submitted a PMA (Premarket Approval) application to the FDA following positive results from SPRAY-CB, which met its primary endpoint and multiple secondary endpoints with statistical significance. The company serves interventional pulmonology specialists and pulmonary care centers. CSA Medical is based in Lexington, Massachusetts, and maintains an active clinical development and regulatory strategy targeting the large COPD patient population (estimated 9 million Americans with chronic bronchitis).

Cambridge Interventional LLC manufactures radiofrequency ablation (RFA) systems for minimally invasive thermal tissue ablation across multiple organ systems. The company's flagship product, the Cambridge CRF System, is an integrated RFA platform comprising a generator-pump unit with real-time audiovisual feedback, low-profile electrodes designed to reduce hand fatigue and improve anatomical clearance, and comprehensive global training and support services. The system is indicated for ablation applications in thyroid nodules, liver tumors, renal masses, bone lesions, uterine fibroids (myomas), and lung tissue. The platform is built on over 70 years of innovation expertise and features advanced algorithms and high power output designed to enable large, controlled ablations with clinical efficacy demonstrated through long-term follow-up data. Cambridge Interventional targets interventional radiologists, endocrinologists, and other clinicians performing image-guided ablative procedures. The company actively participates in major medical society meetings including the American Thyroid Association (ATA), Western Angiographic & Interventional Society (WAIS), and American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF). The company emphasizes ease of use and clinical outcomes optimization across both experienced and novice operator profiles.

Echosens is a pioneer in non-invasive liver health assessment, headquartered in Westborough, Massachusetts. The company manufactures and distributes FibroScan®, the global reference standard for liver fibrosis and liver steatosis assessment. FibroScan® uses Vibration-Controlled Transient Elastography (VCTE) technology to enable non-invasive, painless evaluation of liver disease without biopsy. With over 6,500 systems installed worldwide across 127+ countries, Echosens has facilitated millions of liver examinations. The technology is supported by over 6,270 peer-reviewed publications and recognition in 250+ international clinical guidelines. Echosens offers multiple product lines: the FibroScan® Family (including FibroScan® Mini, a portable variant); Guided VCTE™ (next-generation assessment platform); Liver Health Management (LHM), a cloud-based solution for comprehensive liver disease monitoring; and Scores solutions that integrate biological markers with FibroScan® data. The company serves hepatology, gastroenterology, infectious disease, primary care, and occupational health settings. Echosens manufactures devices with uniform algorithms designed to minimize inter-operator variability and eliminate inter-system variability, supporting evidence-based clinical decision-making. The company operates a global distribution network and provides trade-in programs for equipment upgrades.

ZETA Surgical Inc. designs and manufactures AI-powered frameless neuronavigation systems for cranial surgery and neuromodulation procedures. The company's core platform, REALTRACK™, delivers real-time image-guided navigation with submillimeter accuracy and live continuous surgical guidance tracking patient movement at 20 times per second. The system eliminates the need for cranial pin fixation and general anesthesia, enabling bedside procedures in operating rooms, emergency settings, and ambulatory surgical centers. Primary clinical applications include external ventricular drain (ventriculostomy) placement, brain biopsy, transcranial magnetic stimulation (TMS) targeting, and tumor resection such as cavernoma removal. Clinical data demonstrates 100% single-pass catheter placement success for ventriculostomy (versus 81% freehand), 100% ideal placement (versus 32% freehand), zero adverse events and revision surgeries. The TMS Navigation System achieved FDA 510(k) clearance in October 2025. ZETA's technology integrates AI-based image analysis, ultra-fast system setup, and real-time guided intervention. The company is backed by leading neurosurgeons and research institutions including Harvard Medical School, Brigham and Women's Hospital, and Imperial College London. ZETA serves hospital operating rooms, neurosurgical centers, and interventional procedure suites primarily in the United States.

Voiant is a clinical trial imaging Contract Research Organization (CRO) specializing in AI-powered imaging solutions for biopharmaceutical companies. With over 30 years of clinical expertise, Voiant delivers high-quality imaging endpoint data and endpoint adjudication services supporting therapies across oncology, ophthalmology, and respiratory indications from Phase I-IV global trials. The company operates a proprietary, purpose-built AI platform that accelerates imaging processing and analysis while maintaining scientific accuracy through expert human oversight. Voiant's services include independent reading center operations, blinded imaging review (BICR), and specialized imaging biomarker analysis. The company has expanded AI capabilities through acquisition of Voxeleron and maintains a global network of subspecialty-trained clinical readers, regulatory expertise, and over 2,700 registered clinical trial sites. Voiant has contributed to multiple FDA-approved therapies and serves as a trusted partner for sponsors, CROs, and clinical research organizations seeking reliable, reproducible imaging endpoint data and faster turnaround times.

Helios Cardio is a cardiac repair and regeneration company developing biologic tissue scaffolds and therapeutic devices for challenging cardiovascular conditions. The company focuses on chronic heart failure, post-surgical complications, and cardiac repair indications with unmet clinical needs. The core technology platform is Fetal Engineered Biologic Matrix (f-EBM), a tissue scaffold combining mechanical strength with a cell-friendly environment to support cardiac tissue regeneration. Their lead product, CardiaMend™ Pericardial and Epicardial Reconstruction Matrix, is FDA-cleared for pericardial and epicardial repair and reconstruction. CardiaMend™ is based on f-EBM and provides mechanical support while facilitating tissue integration and regeneration. Helios Cardio is investigating f-EBM as both monotherapy (e.g., ventricular restraint in heart failure) and in combination with cellular therapies (autologous or induced pluripotent stem cells) and pharmacotherapies. The company is led by a team with 20+ years of regenerative medicine experience and is advised by cardiac surgeons active in clinical research. Products address coronary heart disease, heart failure, and post-operative atrial fibrillation—conditions affecting millions of patients with significant annual mortality and healthcare costs.

Anika Therapeutics is a global leader in hyaluronic acid (HA)-based orthopedic regenerative solutions and osteoarthritis pain management. Founded with 30+ years of HA expertise, the company develops and markets innovative treatments addressing rotator cuff and tendon repair, cartilage regeneration, bone augmentation, and non-opioid osteoarthritis pain management. The company operates through two primary product platforms: Regenerative Solutions (tissue repair and scaffold-based regeneration) and OA Pain Management (HA viscosupplements and combination therapies). Key products include Integrity (HA-based rotator cuff and tendon repair augmentation), Hyalofast (cartilage regeneration scaffold), Tactoset (injectable bone substitute), NanoFx (bone marrow stimulation), Cingal (combination HA + steroid injection), Monovisc (single-injection HA viscosupplement), and Orthovisc (multi-injection HA viscosupplement). Products are clinically validated with robust safety and efficacy data supporting use in orthopedic surgery and rheumatology. Anika maintains US headquarters in Bedford, MA, with operational offices in Warsaw, IN, and significant EU presence in Padova, Italy. The company distributes products in 45+ countries globally through direct sales, distribution partnerships, and strategic alliances including J&J MedTech for US Orthovisc and Monovisc distribution. Regulatory credentials and certifications align with FDA, CE marking, and ISO standards for medical devices. The company serves orthopedic surgeons, rheumatologists, pain management specialists, and healthcare institutions seeking regenerative and conservative OA treatment alternatives.

HEMEDEX INC., founded in 2000, commercializes proprietary MIT-derived technology for real-time quantification of tissue perfusion and cerebral blood flow (CBF) at the capillary level. The company's patented thermal diffusion microprobe-based platform is designed for use in neurocritical care and neurosurgical settings, providing clinicians with continuous, absolute measurements of cerebral perfusion during complex procedures involving compromised vasculature, traumatic brain injury, subarachnoid hemorrhage, and other acute neurological conditions. The Bowman Perfusion Monitor enables bedside multimodal neuromonitoring for up to ten days, offering early warning of tissue ischemia and rapid assessment of intervention efficacy. ISO 13485:2012 certified medical device manufacturer serving leading academic medical centers and neuro ICUs across North America.

TISSIUM is a medical device company founded in 2013 that develops biomorphic programmable polymers for tissue reconstruction and repair. The company's proprietary technology platform consists of biocompatible polymer building blocks that can be customized to match tissue-specific requirements while conforming to and integrating with surrounding tissue. TISSIUM currently markets COAPTIUM® CONNECT, the first and only FDA-authorized system for atraumatic sutureless nerve coaptation in peripheral nerve repair, which is commercially available in the United States. The company has received FDA De Novo clearance for its lead product and has completed two clinical studies, with 10 peer-reviewed publications and 26 patent families filed (88 patents granted). TISSIUM's pipeline extends across multiple therapeutic areas including peripheral nerve, cardiovascular, and gastrointestinal applications, with both open surgical and minimally invasive procedure formats. The company operates as a medical device manufacturer with focus on surgical reconstruction solutions for patients with damaged or injured tissue. Regulatory credentials include FDA De Novo authorization and adherence to medical device manufacturing standards.

Computer Sports Medicine, Inc. (CSMi) is a family-owned manufacturer of computer-based measurement, training, and documentation solutions for athletic training, exercise science, and physical therapy. Founded in 1982 and based in Stoughton, Massachusetts, CSMi serves hospitals, clinics, research centers, training rooms, industrial sites, and educational institutions across 30+ countries. The company's flagship product, HUMAC NORM, is a gold-standard isokinetic testing and rehabilitation system offering four resistance modes and 22 isolated-joint patterns for objective strength assessment and functional rehabilitation across shoulder, elbow, wrist, hip, knee, and ankle. CSMi also provides SportsWareOnLine, a HIPAA- and FERPA-compliant web-based electronic medical record (EMR) platform purpose-built for athletic trainers to document injuries, treatments, and return-to-play decisions, already managing records for over four million athletes worldwide. The company's integrated solutions enable clinicians, researchers, and athletic professionals to collect objective data, track recovery outcomes with confidence, and support evidence-based rehabilitation protocols.

Fortis Life Sciences is a strategic platform company based in Waltham, Massachusetts, founded in August 2020. It operates as a multi-subsidiary life sciences tools provider delivering specialized reagents, diagnostic components, and custom development services to biopharma, diagnostics, and research organizations globally. The company integrates five ISO 13485 certified and GMP-compliant North American manufacturing and R&D locations under its "Farm-to-Bench" system, spanning antibody discovery and production, viral vector manufacturing, nanoparticle synthesis, molecular biology reagents, and diagnostic component CDMO services. Core product portfolio includes premium monoclonal and recombinant antibodies (validated for ELISA, Western blot, IHC, flow cytometry, spatial biology), VHH domain libraries (AbNano platform), lateral flow immunoassay components, assay-grade enzymes and master mixes, diagnostic grade nanoparticles (gold, platinum, silica), and lentiviral and AAV vector production. The company also offers contract manufacturing, antibody development, spatial biology imaging services, and precision lyophilization for stable diagnostic products. It serves over 10,000 customers across biopharma, diagnostics OEMs, contract manufacturers, academic research, and applied technology sectors.

Epicore Biosystems is a digital health and biomedical wearables company specializing in sweat-sensing microfluidic technology. The company develops non-invasive biowearable devices that analyze sweat biomarkers—including electrolytes, metabolites, nutrients, and stress markers—to provide real-time physiological insights. Epicore's proprietary sweat microfluidic sensing platform integrates cloud analytics for personalized health monitoring and decision support. The company's primary solutions target three market segments: industrial safety (workplace hydration and heat stress monitoring), sports and fitness (performance optimization and recovery tracking), and clinical research (biomarker discovery and FDA-registered data collection systems). Epicore's Connected Hydration platform delivers continuous monitoring with real-time alerts, and its Discovery Patch provides laboratory-grade sweat analysis for research applications. The company has established partnerships with major enterprises including Chevron, PepsiCo, Gatorade, and the U.S. Air Force Research Laboratory, deploying solutions across energy, construction, and professional sports sectors.

Belmont Medical Technologies is a medical device manufacturer specializing in fluid warming, fluid management, and patient temperature regulation solutions for critical care environments. The company develops precision-controlled devices designed for hospitals, surgical centers, emergency transport, military combat fields, and EMS settings. Belmont's portfolio addresses hypothermia prevention, intraoperative normothermia maintenance, and therapeutic temperature management. The Belmont® Rapid Infuser RI-2 delivers warmed blood and fluids at rates from 2.5 to 1000 ml/min with automatic air detection; buddy lite® provides portable, battery-powered warming for field and transport use; Allon® and CritiCool® systems maintain perioperative body temperature non-invasively using algorithm-driven heat pumps and disposable patient garments; and the Hyperthermia Pump™ performs intraperitoneal and thoracic hyperthermic lavage with electromagnetic induction heating. All disposables are aluminum-free and feature intuitive touchscreen interfaces. Belmont has earned significant U.S. military contracts for fluid resuscitation and temperature management.

Product Resources is a US-based contract engineering and manufacturing company specializing in complex scientific instrumentation, medical devices, and industrial automation. Founded in 1979 and based in Newburyport, Massachusetts, the company provides end-to-end design and manufacturing services including product design, prototype development, design for manufacturability, regulatory compliance, pilot production, and full-scale manufacturing with assembly and testing. The company is FDA-registered and ISO 13485:2016 certified for medical device manufacturing, with additional ISO 9001:2015 certification and specialized expertise in design and manufacturing for explosive atmospheres (UL913, ATEX). Product Resources has manufactured diverse products including microfluidic dispensing systems, dental laser instruments, surgical robot navigation systems, pharmaceutical process equipment, cryogenic sample preparation devices, automated chemistry lab equipment, and control systems for medical devices. The company serves OEMs, medical device manufacturers, and technical startups across North America, Europe, and Japan, with approximately half of products exported globally.